ASTRAZENECA

AstraZeneca sees pivotal lung cancer trial results later in 2018

AstraZeneca sees pivotal lung cancer trial results later in 2018

Published 12/03/2018

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File PhotoLONDON (Reuters) - AstraZeneca [more…]

AstraZeneca’s immunotherapy drug wins key lung cancer approval

AstraZeneca’s immunotherapy drug wins key lung cancer approval

Published 17/02/2018

FILE PHOTO: A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File PhotoLONDON (Reuters) - AstraZeneca’s immunotherapy drug [more…]

AstraZeneca is sued by Array BioPharma over cancer drug royalties

AstraZeneca is sued by Array BioPharma over cancer drug royalties

Published 02/02/2018

NEW YORK (Reuters) - Array BioPharma Inc on Thursday sued AstraZeneca AB, accusing the pharmaceutical company of refusing to pay required royalties for a cancer [more…]

AstraZeneca’s three-in-one inhaler helps COPD patients in trial

AstraZeneca’s three-in-one inhaler helps COPD patients in trial

Published 26/01/2018

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo(Reuters) - AstraZeneca said an inhaler for chronic [more…]

AstraZeneca steps up China push with new drug joint venture

AstraZeneca steps up China push with new drug joint venture

Published 27/11/2017

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File PhotoLONDON (Reuters) - Drugmaker [more…]

AstraZeneca gets breakthrough status for blood cancer drug

AstraZeneca gets breakthrough status for blood cancer drug

Published 01/08/2017

FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014.

AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

[more…]

New test may turn AZ`s Lynparza into precision drug for prostate cancer

New test may turn AZ`s Lynparza into precision drug for prostate cancer

Published 18/06/2017

FILE PHOTO: The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014. REUTERS/Stefan Wermuth/File Photo

Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

[more…]

Newer type 2 diabetes drugs show heart protective quality in study

Newer type 2 diabetes drugs show heart protective quality in study

Published 19/03/2017

A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released on Sunday from a so-called real world study sponsored by AstraZeneca.

[more…]

AstraZeneca receives fresh blow to potassium drug

AstraZeneca receives fresh blow to potassium drug

Published 17/03/2017

FILE PHOTO: The logo of AstraZeneca is seen on a medication package at a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo

AstraZeneca said on Friday that U.S. regulators had rejected the British company's new drug for high potassium levels, in the latest setback to the product.

[more…]

AstraZeneca ovarian cancer drug slows disease markedly in study

AstraZeneca ovarian cancer drug slows disease markedly in study

Published 14/03/2017

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble

AstraZeneca's ovarian cancer drug Lynparza slashed the risk of disease progression in a closely watched clinical trial, boosting its profile against rivals within the novel PARP inhibitor drug class.

[more…]